Sat, Sep 20, 2014, 1:48 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ADVANCED CELL TECH Message Board

biocoach98 1 post  |  Last Activity: Aug 27, 2014 4:47 PM Member since: Dec 9, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • What is a technology/company worth that halts, or even reverses, macular degeneration? Currently ACTC market cap. = ~275 Million. Current treatment "Eylea" from REGN (Market Cap= ~34 B) only slows the progression of decline. It seems to me that the market potential will dictate the projected value of the product and corresponding share price. If this is the real deal, with positive data release, I personally like the 1:100 ratio. ~35 million shares outstanding is a very comfortable number for a growing and promising biotechnology company -leaving options on the table for future fund-raising if warranted.

ACTC
0.08150.0000(0.00%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TC PipeLines, LP
NYSEFri, Sep 19, 2014 4:00 PM EDT